05 Compliance

The regulatory file for β-NAD

Technical document 05 · Reviewed 2026-11-19 · NAD+

On this page
  1. The supplier-side file
  2. European Union route
  3. United States route
  4. Ingredient limits and the finished product
  5. Naming the ingredient and reviewing claims
  6. The document set
  7. Pre-order checks

β-NAD is sold to the catalog specification, but whether and how it can be used is a destination question. This page does not assert a novel-food authorisation, a new dietary ingredient (NDI) notification or a permitted-ingredient status for any market. The buyer's regulatory team confirms the route, the dose and the label; the supplier's job is to make the specification, the certificate and the supporting statements accurate and current.

In one line

The specification covers the powder; the route, the dose and the label are destination questions for the buyer's regulatory team.

The supplier-side file

The supplier-side file has to be complete before the route question can be answered: which specification version, which lot, which results, which statements. A reviewer who has to chase a missing allergen declaration cannot finish the assessment.

Build it around the material, not the folder. One specification revision, one COA per lot, one TDS, one SDS, and dated statements for allergens, GMOs, origin, residual solvents and change control. A folder of scans with no revision dates is not a file.

European Union route

Five instruments frame the EU review: general food law (Regulation (EC) No 178/2002), food information and labelling (Regulation (EU) No 1169/2011), food supplements (Directive 2002/46/EC), contaminants (Regulation (EU) 2023/915) and, when the substance is not established, the novel food Regulation (EU) 2015/2283.

A novel-food authorisation is tied to a substance, a form, a use level and a food category. The catalog does not assert that such an entry covers β-NAD. The buyer's regulatory team checks the current consolidated text, the form and the conditions for the destination.

United States route

On the US side, the route runs through the Federal Food, Drug, and Cosmetic Act as amended by DSHEA. A dietary ingredient marketed before 15 October 1994 falls under the pre-DSHEA provision; a newer one is normally supported by an NDI notification under 21 CFR Part 190. 21 CFR Part 111 and 21 CFR 101.36 govern manufacturing and the Supplement Facts panel.

This page does not assert that an NDI notification exists for β-NAD or that it covers this form and dose. The buyer confirms the basis and keeps the evidence.

Ingredient limits and the finished product

The catalog's metal limits apply to the ingredient. The finished product is a separate calculation: lot result times dose, compared with the limit for the destination. The arithmetic belongs in the file.

Contaminant panel: catalog limits and the file check
ParameterCatalog limitWhat the file confirms
Lead (Pb)≤3 mg/kgLot result, method and finished-product calculation
Arsenic (As)≤2 mg/kgLot result and the destination limit that applies
Cadmium (Cd)≤1 mg/kgLot result and any category exception
Mercury (Hg)≤0.1 mg/kgLot result and method
MicrobiologyAPC ≤1,000 cfu/g; yeast and mould ≤100 cfu/g; E. coli and Salmonella absentThe lot count and the absence statement

Micro results release a lot; they do not make it sterile. Keep the retained sample so that a contested result can be re-examined.

Naming the ingredient and reviewing claims

No disease-related claim is made here. The label should name the ingredient in full as well as the abbreviation; structure/function wording needs substantiation and a market check. Claims sit outside the specification, and a certificate cannot authorise one.

Age-related or metabolic wording is still a claim. Artwork review needs the finished dose, the form and the destination in front of the reviewer.

The document set

  • Specification with a version number, the form and the CAS number.
  • Batch COA for the lot, with the assay basis, water by Karl Fischer and pH.
  • Technical and safety data sheets, both current.
  • Allergen, GMO and origin statements.
  • Residual-solvent statement for the route that was used.
  • Metals and micro results for the specific lot.
  • Stability summary covering the pack on order.
  • Change-control statement for source, process and pack.

Date and revision every document. The quotation, the specification and the certificate should name the same version. A missing statement is easier to fix before the order than after the container is loaded.

Pre-order checks

  • Form, CAS number and specification version are named.
  • The buyer's regulatory team has confirmed the destination route.
  • The use level and the finished-product dose are inside that route.
  • The certificate and specification are on file, with the assay basis and water result.
  • Technical and safety data sheets are current.
  • Allergen, GMO, origin and residual-solvent statements are dated.
  • The heavy-metal results are converted to the finished-product dose.
  • Label wording and claims have been checked against the destination rules.

Catalog values are on the NAD+ product page. What a lot certificate reports is set out on the COA page, and the analytical tests are on the identity page. Framework references are collected in the EU regulatory note, and the release file is described on the quality page.

Send the specification you intend to use — grade, quantity and destination market — and we will reply with the batch COA, the technical data sheet and a quotation.

Request a quotation